Drug intelligence / Profile preview

APHD-002

Development stage: Unknown
Lead developer: Aphaia Pharma
Modality: Small Molecules
Administration: Oral

Overview

APHD-002 is a distal jejunal-release formulation of dextrose beads developed by Aphaia Pharma for the treatment of obesity and associated weight-related comorbidities. The drug utilizes a specialized delivery system designed to bypass the proximal small intestine and release dextrose specifically in the distal jejunum. This targeted delivery aims to restore endogenous nutrient-sensing signaling pathways and stimulate natural hormone release patterns (such as GLP-1 and PYY) that are often blunted in individuals with obesity. APHD-002 represents a specific dose formulation within Aphaia's pipeline and is currently being evaluated in Phase II clinical trials, sometimes in combination with other compositions to enhance its metabolic effects.

Other names: dextrose beadsdistal jejunal-release dextrose beads

Beyond the preview

Go deeper on APHD-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APHD-002.

Explore the full profile